ImageneBio Net Income
| IMA Stock | 6.91 0.10 1.43% |
As of the 7th of February, ImageneBio retains the Standard Deviation of 3.67, risk adjusted performance of (0.04), and Market Risk Adjusted Performance of (0.66). ImageneBio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
ImageneBio Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 31.8591 | Revenue | Earnings Share (4.33) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -44.3 M | -46.5 M | |
| Net Loss | -32.9 M | -34.6 M | |
| Net Loss | (0.68) | (0.72) | |
| Net Income Per E B T | 0.90 | 0.80 |
ImageneBio | Net Income | Build AI portfolio with ImageneBio Stock |
Analyzing ImageneBio's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing ImageneBio's current valuation and future prospects.
Latest ImageneBio's Net Income Growth Pattern
Below is the plot of the Net Income of ImageneBio over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in ImageneBio financial statement analysis. It represents the amount of money remaining after all of ImageneBio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is ImageneBio's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ImageneBio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (49.23 M) | 10 Years Trend |
|
Net Income |
| Timeline |
ImageneBio Net Income Regression Statistics
| Arithmetic Mean | (41,408,233) | |
| Coefficient Of Variation | (28.80) | |
| Mean Deviation | 6,701,447 | |
| Median | (40,865,000) | |
| Standard Deviation | 11,925,882 | |
| Sample Variance | 142.2T | |
| Range | 51.9M | |
| R-Value | (0.08) | |
| Mean Square Error | 150.7T | |
| R-Squared | 0.01 | |
| Significance | 0.76 | |
| Slope | (192,805) | |
| Total Sum of Squares | 2275.6T |
ImageneBio Net Income History
Other Fundumenentals of ImageneBio
ImageneBio Net Income component correlations
ImageneBio Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ImageneBio is extremely important. It helps to project a fair market value of ImageneBio Stock properly, considering its historical fundamentals such as Net Income. Since ImageneBio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ImageneBio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ImageneBio's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImageneBio. Market participants price ImageneBio higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ImageneBio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
ImageneBio's market price often diverges from its book value, the accounting figure shown on ImageneBio's balance sheet. Smart investors calculate ImageneBio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since ImageneBio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between ImageneBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImageneBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImageneBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ImageneBio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ImageneBio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ImageneBio.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in ImageneBio on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding ImageneBio or generate 0.0% return on investment in ImageneBio over 90 days. ImageneBio is related to or competes with Connect Biopharma, InflaRx NV, Kalaris Therapeutics, Shattuck Labs, Context Therapeutics, Sutro Biopharma, and Artiva Biotherapeutics. ImageneBio is entity of United States. It is traded as Stock on NASDAQ exchange. More
ImageneBio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ImageneBio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ImageneBio upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 18.29 | |||
| Value At Risk | (5.18) | |||
| Potential Upside | 6.76 |
ImageneBio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ImageneBio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ImageneBio's standard deviation. In reality, there are many statistical measures that can use ImageneBio historical prices to predict the future ImageneBio's volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.27) | |||
| Total Risk Alpha | (0.60) | |||
| Treynor Ratio | (0.67) |
ImageneBio February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.66) | |||
| Mean Deviation | 2.5 | |||
| Coefficient Of Variation | (1,591) | |||
| Standard Deviation | 3.67 | |||
| Variance | 13.48 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.27) | |||
| Total Risk Alpha | (0.60) | |||
| Treynor Ratio | (0.67) | |||
| Maximum Drawdown | 18.29 | |||
| Value At Risk | (5.18) | |||
| Potential Upside | 6.76 | |||
| Skewness | 1.36 | |||
| Kurtosis | 3.17 |
ImageneBio Backtested Returns
ImageneBio holds Efficiency (Sharpe) Ratio of -0.0555, which attests that the entity had a -0.0555 % return per unit of risk over the last 3 months. ImageneBio exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out ImageneBio's Market Risk Adjusted Performance of (0.66), risk adjusted performance of (0.04), and Standard Deviation of 3.67 to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.36, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, ImageneBio's returns are expected to increase less than the market. However, during the bear market, the loss of holding ImageneBio is expected to be smaller as well. At this point, ImageneBio has a negative expected return of -0.21%. Please make sure to check out ImageneBio's potential upside, day median price, and the relationship between the total risk alpha and accumulation distribution , to decide if ImageneBio performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.61 |
Very good reverse predictability
ImageneBio has very good reverse predictability. Overlapping area represents the amount of predictability between ImageneBio time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ImageneBio price movement. The serial correlation of -0.61 indicates that roughly 61.0% of current ImageneBio price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.61 | |
| Spearman Rank Test | -0.57 | |
| Residual Average | 0.0 | |
| Price Variance | 0.16 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ImageneBio Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, ImageneBio reported net income of (49.23 Million). This is 114.43% lower than that of the Biotechnology sector and 170.29% lower than that of the Health Care industry. The net income for all United States stocks is 108.62% higher than that of the company.
ImageneBio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImageneBio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ImageneBio could also be used in its relative valuation, which is a method of valuing ImageneBio by comparing valuation metrics of similar companies.ImageneBio is currently under evaluation in net income category among its peers.
ImageneBio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ImageneBio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ImageneBio's managers, analysts, and investors.Environmental | Governance | Social |
ImageneBio Fundamentals
| Operating Margin | (5.01) % | ||||
| Current Valuation | 111.51 M | ||||
| Shares Outstanding | 11.18 M | ||||
| Shares Owned By Insiders | 14.24 % | ||||
| Shares Owned By Institutions | 33.98 % | ||||
| Number Of Shares Shorted | 384.41 K | ||||
| Price To Sales | 21.32 X | ||||
| Revenue | 3.5 M | ||||
| Gross Profit | 4.3 M | ||||
| EBITDA | (35.47 M) | ||||
| Net Income | (49.23 M) | ||||
| Total Debt | 7.52 M | ||||
| Book Value Per Share | (0.43) X | ||||
| Cash Flow From Operations | (46 M) | ||||
| Short Ratio | 1.31 X | ||||
| Earnings Per Share | (4.33) X | ||||
| Target Price | 30.0 | ||||
| Market Capitalization | 91.69 M | ||||
| Total Asset | 141.51 M | ||||
| Retained Earnings | (331.62 M) | ||||
| Working Capital | (4.74 M) | ||||
| Net Asset | 141.51 M |
About ImageneBio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImageneBio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImageneBio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImageneBio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ImageneBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImageneBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Imagenebio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Imagenebio Stock:Check out For information on how to trade ImageneBio Stock refer to our How to Trade ImageneBio Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImageneBio. Market participants price ImageneBio higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ImageneBio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
ImageneBio's market price often diverges from its book value, the accounting figure shown on ImageneBio's balance sheet. Smart investors calculate ImageneBio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since ImageneBio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between ImageneBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImageneBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImageneBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.